1	
2	The accuracy of machine learning models using
3	ultrasound images in prostate cancer diagnosis: A
4	systematic review
5	
6	Retta C Sihotang ¹ , Claudio Agustino ¹ , Ficky Huang ¹ , Dyandra Parikesit ² , Fakhri
7	Rahman ¹ , Agus Rizal AH Hamid ¹
8	
9	¹ Department of Urology, Faculty of Medicine Universitas Indonesia, Cipto
10	Mangunkusumo Hospital, Jakarta, Indonesia
11	² Urology Medical Staff Group, Universitas Indonesia Hospital, Universitas Indonesia,
12	Depok, Indonesia.
13	
14	Corresponding author: Agus Rizal A. Hamid
15	Mailing address: Faculty of Medicine, Universitas Indonesia, No.6, Salemba Raya Road,
16	DKI Jakarta, 10430, Indonesia
17	Tel.: +621-3912477
18	Mobile Phone: +628111803377
19	Email: rizalhamid.urology@gmail.com
20	

21 **ABSTRACT**

22 Prostate Cancer (PCa) is the third most commonly diagnosed cancer worldwide, and its 23 diagnosis requires many medical examinations, including imaging. Ultrasound offers a 24 practical and cost-effective method for prostate imaging due to its real-time availability at 25 the bedside. Nowadays, various Artificial Intelligence (AI) models, including Machine 26 learning (ML) with neural networks, have been developed to make an accurate diagnosis. 27 In PCa diagnosis, there have been many developed models of ML and the model 28 algorithm using ultrasound images shows good accuracy. This study aims to analyse the 29 accuracy of neural network machine learning models in prostate cancer diagnosis using 30 ultrasound images. The protocol was registered with PROSPERO registration number 31 CRD42021277309. Three reviewers independently conduct a literature search in five 32 online databases (MEDLINE, EBSCO, Proquest, Sciencedirect, and Scopus). We 33 screened a total of 132 titles and abstracts that meet our inclusion and exclusion criteria. 34 We included articles published in English, using human subjects, using neural networks 35 machine learning models, and using prostate biopsy as a standard diagnosis. Non 36 relevant studies and review articles were excluded. After screening, we found six articles 37 relevant to our study. Risk of bias analysis was conducted using QUADAS-2 tool. Of the 38 six articles, four articles used Artificial Neural Network (ANN), one article used Recurrent Neural Network (RNN), and one article used Deep Learning (DL). All articles suggest a 39 40 positive result of ultrasound in the diagnosis of prostate cancer with a varied ROC curve 41 of 0.76-0.98. Several factors affect AI accuracy, including the model of AI, mode and type 42 of transrectal sonography, Gleason grading, and PSA level. Although there was only 43 limited and low-moderate quality evidence, we managed to analyse the predominant

findings comprehensively. In conclusion, machine learning with neural network models is a potential technology in prostate cancer diagnosis that could provide instant information for further workup with relatively high accuracy above 70% of sensitivity/specificity and above 0.5 of ROC-AUC value. Image-based machine learning models would be helpful for doctors to decide whether or not to perform a prostate biopsy.

49

50 Keywords: Machine learning, Artificial Intelligence, Neural Networks, Prostate Cancer,

51 Ultrasonography

52

53 Introduction

Prostate cancer (PCa) is the third most common cancer globally and the second most 54 55 common cancer in men. In 2020, there were an estimated 1,4 million new cases and 56 375,000 new prostate cancer deaths worldwide.[1] There are several modalities to diagnose PCa, including digital rectal examination (DRE), prostate-specific antigen (PSA) 57 58 levels, biomarkers, imaging, and histopathology. The current gold standard for PCa 59 detection in core needle biopsy, performed under transrectal ultrasound (TRUS) guidance.[2-5] The role of ultrasound (US) in this procedure is not for targeting PCa but 60 61 for anatomical navigation. Aside from the complications associated with the biopsy, high 62 levels of underdiagnosed and overtreatment have been reported.[6-7]

63

64 Ultrasound is a potential candidate for PCa imaging because it is cost-effective, practical,
65 and widely available. The problem of ultrasound images interpretation is that hypoechoic
66 areas suspected of cancer can be normal or cancerous histologically. Most prostate

67 cancers are hypoechoic on TRUS, whereas 30%-40% of prostate cancer are isoechoic, and 1.5% are hyperechoic.[8] The sensitivity and specificity of TRUS are limited, ranging 68 between 40% and 50% for detecting PCa.[8,9] Several studies depict that using grey 69 70 mode US alone is inadequate for PCa screening.[10] However, there are several new 71 modes of US in prostate gland imaging, such as contrast-enhanced ultrasound (CEUS), 72 color Doppler and ultrasound elastography. CEUS is an ultrasound technique that uses 73 intravenous injected gas-filled microbubbles as a contrast agent to provide microvascular 74 and tissue perfusion information.[11] Color Doppler mode has capability to detect motion 75 or blood flow using a color map to show the speed and direction of blood flow through 76 vessel.[12] Ultrasound elastography is a non-invasive imaging technique to measure 77 changes in soft tissue elasticity.[13] Those new modes increase overall accuracy in 78 detecting PCa in comparison to grey mode. [10-17] However, the diagnostic performance of those modes is still not quite satisfactory with a wide range of sensitivity (67% to 93%) 79 80 and specificity (59% to 93%).[12-13,16-17]

81

82 Artificial Intelligence (AI) is defined as an ability of a computer to perceive the surrounding 83 environment and make the same decisions as a human intellect on an action to reach a 84 particular goal [18] AI is now a revolutionising technology in the healthcare field and is 85 gaining interest. Machine learning (ML) is a branch of AI that focuses on using data and 86 algorithms to improve accuracy. To train machine learning, it is enough to acquire structured datasets consisting of input variables and outcomes. Al has a vital role in 87 88 interpreting large amounts of data. Neural networks (such as artificial neural networks – 89 ANN, convolutional neural networks – CNN, recurrent neural networks – RNN) are

90 machine learning models which work like human biological neuron. They have ability to 91 learn and model non-linear and complex relationships that enable them to generate 92 relationships between inputs and outputs in a complex pattern. The developed algorithm 93 of machine learning may help urologists to reduce the number of unnecessary prostate 94 biopsies without missing the diagnosis of aggressive PCa.[19]

95

96 In PCa, AI has been shown to aid in a standardised pathological grading to assess cancer 97 stratification and treatment. Numerous studies have evaluated the utility of prostate 98 specific antigen (PSA) and/or magnetic resonance imaging (MRI) in the setting of AI in 99 detecting prostate cancer. Nitta et al. [20] and Djavan et al. [21] applied machine learning 100 models to predict prostate cancer based on PSA levels. Machine learning tends to be 101 superior to the conventional methods with ROC-AUC ranging from 0.63-0.91 based on 102 the machine learning models and PSA categories. Aldoj et al. [22] utilized AI using MRI 103 with 3D combinations (apparent diffusing coefficient (ADC), diffusion weighted imaging 104 (DWI), and T2 weighted images) which generated sensitivity at 81.2% and specificity at 105 90.5%. The high diagnostic performance is also found in a study by Yoo et al. [23] using 106 deep CNN analysis of DWI sequence with ROC-AUC of 0.84-0.87. However, the 107 accuracy of machine learning using ultrasound data as the primary modality remains 108 debatable. This review aims to analyse the accuracy of neural networks ML models using 109 ultrasound images in prostate cancer diagnosis.

110

111 Methods

112 **Protocol Registration**

- 113 The protocol for this systematic review was registered with PROSPERO registration
- 114 number CRD42021277309.
- 115

116 Search Strategy

Three reviewers independently (RC, CA, FH) conducted a literature search in five online databases (MEDLINE, EBSCO, Proquest, ScienceDirect, and Scopus) on November 19 19th, 2021. The keywords used were "Prostate Cancer" AND "Machine Learning" AND "Diagnosis" AND "Ultrasonography with various combinations as written in **Table 1**. The researcher also reviewed the reference list of chosen articles from the literature search to identify relevant studies.

- 123
- 124 **Table 1**. Literature search strategy

Database	Keywords	Result	Date attempt
PubMed	(((prostate cancer or prostate	78	November 19 th ,
	carcinoma) AND ((((imaging) OR		2021
	(Ultrasonography)) OR		
	(transrectal ultrasonography)) OR		
	(TRUS))) AND ((diagnostic		
	outcome) AND (diagnosis))) AND		
	((((machine learning) OR (deep		
	learning)) OR (artificial neural		
	network)) OR (convolutional		

	neural network))		
EBSCO	machine learning or artificial	7	November 19 th ,
	intelligence or deep learning or		2021
	neural network AND prostate		
	cancer AND ultrasound or		
	sonography or ultrasonography		
	[Title]		
Proquest	ab(prostate cancer) AND	4	November 19 th ,
	ab(ultrasound) AND ab(artificial		2021
	neural network OR machine		
	learning) AND ab(diagnosis)		
Sciencedirect	Title, abstract, keywords: (prostate	13	November 19 th ,
	cancer) AND (ultrasound) AND		2021
	(machine learning OR neural		
	network) AND (diagnosis)		
	[research articles]		
Scopus	TITLE-ABS-	43	November 19 th ,
	KEY (machine AND learning AN		2021
	D ultrasound AND prostate AN		
	D cancer AND diagnosis)		

126 Study Selection and Data Extraction

127 We included all available articles about machine learning use in prostate cancer diagnosis 128 that used ultrasound images. We restricted our search to articles published in English 129 without a publication date limit. A study was considered relevant if it fulfilled our inclusion 130 criteria: using human subjects, using neural networks machine learning models, and 131 using prostate biopsy as a standard diagnosis. We included cohort, case-control, and 132 cross-sectional studies. An article was excluded from the selection if it was a 133 conference/review article, combination examination with MRI, or no diagnostic parameter in the article. All reviewers screened the title and abstract of the selected papers 134 135 independently. Discrepancies between the reviewers were solved through discussion 136 with the senior reviewers (DP, ARAH, and FR) until the consensus was reached. All 137 authors agreed on the final list of selected papers for extraction. The PRISMA flow 138 diagram is used to guide the article selection process.

139

140 **Risk of Bias Assessment**

Three reviewers independently evaluated the methodological quality of the studies using the QUADAS-2 Tool in Review Manager software 5.4 version. The reviewers were not blinded for the author, journal, or publication identities of each article. The risk of bias assessment consists of three categories: high, unclear, or low risk of bias based on the pre-listed questions in the QUADAS-2 Tools.

146

147

149 **Results**

150 Our electronic search identified 145 articles and only 6 that met our inclusion and 151 exclusion criteria (Fig 1). Four articles use the artificial neural networks (ANN) method, 152 one article uses the recurrent neural network (RNN) method, and one article uses the 153 deep learning (DL) method. The characteristics of each study are described in Table 2. 154 The six included studies used a cross-sectional study design. All articles studied adult 155 male human subjects with an unknown age range due to the unclear data. The sample 156 size ranges from 61 to 1077 patients; however, a study from Ronco et al.[24] only 157 provided the number of cases. 158 Figure 1. Prisma Flow Diagram 159 160 161 The quality assessment of the six included articles is shown in **Fig 2** using the QUADAS-2 162 Tool. Several articles have an unclear and high risk of bias. However, we still included 163 the articles in our analysis. The unclear risk of bias is most commonly found in Index Test 164 parameters because of the unclear threshold of the Index test. The high risk of bias is 165 also most commonly found in Index Test parameters due to the results were interpreted

- 166 with the knowledge of reference standard results in several articles.[24-26]
- 167

168 **Figure 2**. Risk of Bias Assessment using QUADAS-2 Tool

169

170 Three articles used TRUS data only for the input parameter and the rest three articles 171 used combination input data from clinical findings. The included studies showed various

- 172 parameters of accuracy analysis, including ROC-area the curve (AUC), positive
- 173 predictive value (PPV), negative predictive value (NPV), sensitivity, and specificity (Table
- 174 **2).** However, a study from Loch et al.²⁵ used percentage only. The performance results
- 175 can be seen in **Table 2.** Due to the varied parameters, a quantitative analysis could not
- be performed. Most of the articles used ROC-AUC as the accuracy parameters.

177	Table 2.	Characteristics	and Performance	Result of	Included	Studies
-----	----------	-----------------	-----------------	-----------	----------	---------

No year Country Samples Inaging Method Results 1 year Variables Accuracy PPV 81.82% 1 NPV 96.95% of NPV 96.95% 1 NPV 96.95% Variables: of 1 Variables: of NPV 96.95% 1 Variables: of NPV 96.95% </th <th>No</th> <th>Author,</th> <th>Country</th> <th rowspan="2">untry Samples</th> <th rowspan="2">Imaging</th> <th>ML</th> <th>Input Data</th> <th>Outcome</th> <th>Performance</th>	No	Author,	Country	untry Samples	Imaging	ML	Input Data	Outcome	Performance
1 Ronco, 1999[24] Uruguay 442 cancer and benign cases Image: Fransrectal ultrasonographic Ultrasonographic variables: of axis Accuracy of NPV 96.95% PPV 81.82% NPV 96.95% 1 Ronco, 1999[24] Uruguay 442 cancer and benign cases Image: Fransrectal ultrasonographic ANN Anteroposterior axis • Longitudinal axis • Prostatic volume • Central zone PPV 81.82%	NO	year	Country			Method			Results
Echoic level	1	Ronco, 1999[24]	Uruguay	442 cancer and benign cases	Transrectal ultrasonograph y	ANN	Ultrasonographic variables: • Transverse axis • Anteroposterior axis • Longitudinal axis • Prostatic volume • Central zone • Echoic level	Accuracy of detecting prostate cancer	PPV 81.82% NPV 96.95%

		• Volume of the	
		pathological	
		area	
		 Major diameter 	
		of the	
		pathological	
		area	
		 Minor diameter 	
		of the	
		pathological	
		area	
		 Presence/abse 	
		nce of	
		calcifications	
		calcifications	



						 Prostatic specific antigen level Number of biopsies 		
2	Loch, 1999[25]	Nevada	553 specimens from 61 patient with confirmed prostate cancer	Transrectal ultrasonograph y	ANN	TRUS Findings	Accuracy of detecting prostate cancer	Benign pathology: 99% classified correctly; Cancer: 71% classified correctly
3	Lee, 2006[26]	Korea	684 patients who had	Transrectal ultrasonograph	ANN	Model 1: • Age	Diagnostic performanc	Model 2 showed

undergone	y and Doppler	DRE findings	e of 2 ANN	better
TRUS-guided	ultrasonograph	PSA level	models	accuracy than
prostate biopsy	У	 PSA density 		Model 1.
		Transitional		
		zone volume		Accuracy M1
		PSA density in		• AUC PSA
		the transitional		0-4: 0.738
		zone		• PSA 4-10:
				0.753
		Model 2:		• PSA>10:0.
		• Age		774
		DRE findings		
		PSA level		Accuracy M2
		PSA density		• AUC PSA
		Transitional		0-4: 0.859
		zone volume		• PSA 4-10:

						•	PSA density in		0.797
							the transitional		PSA>10:0.89
							zone		4
						•	TRUS findings		
							(positive,		
							suspicious,		
							negative)		
						•	Age	Accuracy	ROC MLRA
			1077 patients	Transrectal		•	DRE findings	of each	0.768
			who had	ultrasonograph	MLRA,	•	PSA level	model	ROC ANN
4	Lee,2009	Korea	undergone	y and Doppler	ANN,	•	PSA density		0.778
	[27]		TRUS guided	ultrasonograph	SVM	•	Transitional		ROC SVM
			prostate biopsy	У			zone volume		0.847
						•	PSA density in		

						 the transitional zone TRUS findings (Class I-V based on lesion location, outline, shape, and vascularity) 		
5	Azizi,201 8[28]	Canada	157 subjects who had undergone prostate biopsy	Temporal enhanced ultrasound	RNN comparin g LTSM, GRU, Vanilla RNN, and	TeUS findings	Accuracy of detecting prostate cancer	LTSM Specificity 0.98 Sensitivity 0.76 Accuracy

		Spectral		0.93
				• AUC 0.96
				GRU
				 Specificity
				0.95
				 Sensitivity
				0.70
				 Accuracy
				0.86
				• AUC 0.92
				Vanilla RNN
				 Specificity
				0.72
				 Sensitivity

				0.69
				 Accuracy
				0.75
				• AUC 0.76
				Spectral
				 Specificity
				0.73
				 Sensitivity
				0.63
				 Accuracy
				0.78
				• AUC 0.76

						TRUS findings	Accuracy	ROC-AUC for
6	Wildeboe	Netherlan d	48 men with confirmed prostate cancer	B-mode US, SWE, and DCE- US	DL		of	Prostate
							multiparam	Cancer 0.75
	1,						etric	ROC-AUC for
	2020[29]						ultrasound	Gleason > 3+
								4 0.90

(ANN: Artificial Neural Network; AUC: Area under the Curve; DCE-U: Dynamic contrast-enhanced ultrasound; DL: Deep
Learning; DRE: Digital Rectal Examination; GRU: Gated Recurrent Units; LTSM: Long Short-Term Memory; MLRA: Multiple
Logistic Regression Analysis; NPV: Negative Predictive Value; PPV: Positive Predictive Value; PSA: Prostate Specific
Antigen; RNN: Recurrent Neural Network; ROC: Receiver Operating Characteristic; SVM: Support Vector Machine; SWE:
Shear-wave Elastograpgy; TRUS: Transrectal sonography)

183 **Discussion**

184 Ultrasound in Prostate Cancer

185 PCa may be suspected when the PSA level increases above normal or if the digital rectal 186 examination (DRE) is abnormal. [2,3] After that, further examinations are carried out to 187 make the diagnosis, including imaging and biopsy as a standard diagnosis. Ultrasound 188 and MRI have been assessed for their ability to reliably detect PCa in men suspected with 189 PCa. MRI allows better visualization of prostate anatomical zones and location of tumor 190 with the extension within the gland. It is useful to allow lesion detection and enable 191 functional imaging of the prostate.[30] The use of MRI as a single modality to detect PCa 192 has been evaluated. Several studies revealed MRI carries a relatively high sensitivity, but 193 poor specificity. Multiparametric MRI has been used widely and shows good sensitivity in 194 larger tumors. However, it is less sensitive to detect lower grade PCa (ISUP Grade 1) 195 with pooled sensitivity of 0.70 and pooled specificity of 0.27.[31] From the current 196 recommendation, multiparametric MRI become the clinical routine examination for 197 patients with suspected PCa and PCa staging.[32-34]

198

Ultrasound is a cost-effective and widely available imaging modality. However, standard TRUS is not a reliable imaging method due to the low sensitivity and specificity in detecting prostate cancer.[5,9,35] TRUS was initially developed with the aim to guide transperineal biopsies. After being evaluated for years, it became evident that cancers of the prostate were most often anechoic or hypoechoic. However, prostatitis and focal infarct also have been reported to have the appearance of hypoechoic lesions on ultrasound, which cause false positive results.[36]

206

207 TRUS has several limitations in basic modes, such as similar backscatter signals of cancerous and normal prostate parenchyma and heterogeneity of the transitional 208 209 zone.[37] Other modes of TRUS such as color Doppler, CEUS, TeUS, and elastography 210 revealed better performance than B-mode.[29,38-39] Recently, innovations have been 211 made to improve accuracy in detecting prostate cancer. Foster et al. developed 212 ultrasound biomicroscopy, performed at frequencies ranging between 14 and 29 MHz, 213 with theoretical spatial resolution at this frequency being between 50 and 70um. This 214 innovation allowed the visualisation of prostate anatomy details that usually could not be 215 seen in conventional US examinations. [40,41] Despite the limitations, TRUS guided 216 biopsy is still the gold standard for the diagnosis pf prostate cancer.

217

218 Although MRI has excellent ability to identify clinically significant PCa, MRI is quite 219 expensive, not portable, and not readily available in healthcare centers. In addition, MRI 220 could not provide real time imaging compared to ultrasound. With such disadvantages, 221 TRUS still has a potential role as imaging modality in prostate cancer diagnosis.[30] A 222 comparative study by Zhang et al showed multiparametric TRUS (grayscale, color 223 Doppler, shear wave elastography, and contrast enhanced ultrasound) had higher 224 sensitivity, negative predictive value, and accuracy than multiparametric MRI (T2-225 weighted, diffusion-weighted, and dynamic contrast-enhanced MRI) in detecting localized 226 PCa.[42] From evidences, TRUS has some advantages in detecting localized PCa from 227 MRI with lower cost, real time, and higher availability.

228

229 Machine Learning increasing the Role of TRUS in Prostate

230 Cancer Diagnosis

231 Ultrasound imaging is limited by operator dependence and poor reproducibility. To read 232 ultrasound images, it requires years of experience and training. To overcome the 233 limitations, machine learning have been developed in medical imaging to accelerate ultrasound image analysis and generate an objective disease classification.[43] In recent 234 235 years, applications of ML to US is developing and rapidly progressing. ML can help by 236 decreasing the time of reader that interprets the amount of data to make a conclusion.[44] 237 ML is a subdiscipline of AI where computer programs learn associations of predictive 238 power from examples of data.[45] Several methods such as classification, regression, 239 registration, and segmentation applied to analyse ultrasound images. However, neural 240 networks algorithms have been shown to significantly improve performance when 241 compared to other classifiers.[43] Neural networks, which work like human brain, gives 242 capability to solve problems based on the available data. This model can incorporate 243 many variables and produce results in more complex situations.[45] In PCa diagnosis, 244 ML can generate input data from various variables to classify whether the patient is 245 suspected of having prostate cancer or not (Fig 3).

246

Figure 3. Schematic Machine Learning Model in Prostate Cancer Diagnosis

Input data includes all available variables that could be beneficial to generate a conclusion. Machine learning modeling consists of complex hidden layers which take an essential role in data processing. The result part is a conclusion of the machine learning build-up algorithm based on the input data.

252

253 Based on our included studies, the overall accuracy of machine learning shows promising 254 results. ROC-AUC values of five studies showed a number greater than 0.5 with a range 255 of 0.75 to 0.98. Wildeboer et al. [29] assessed the potential DL model based on TRUS's 256 B-mode, SWE, and DCE-US. The multiparametric classifier reached ROC-AUC of 0.90 257 compared to 0.75 of the best performing individual parameter for PCa and Gleason >3 + 258 4 significant PCa. The study revealed that combinations of the available modes were 259 favoured compared to single-mode. Lee et al. [26] evaluated the accuracy of the multiple 260 logistic regression model, ANN model, and support vector machine model to predict 261 prostate biopsy outcomes. The models were constructed from the input data of age, DRE 262 findings, PSA parameters, and TRUS findings. This study showed that image-based 263 clinical decision support systems (ANN and SVM) have better accuracy than the multiple 264 logistic regression model. However, SVM was superior to the performance of both ANN 265 and the multiple logistic regression model. Lee et al. [27] evaluated the diagnostic 266 performance of the ANN model with and without TRUS data. This study included 684 267 patients who underwent prostate biopsy, with 214 confirmed to have prostate cancer. 268 ANN model was used with primary input data of age, PSA levels, and DRE findings. 269 However, with additional TRUS data, the accuracy of the ANN model was found to be 270 more accurate with a higher value of ROC-AUC. Azizi et al. [28] proposed temporal 271 modeling of TeUS using RNN to improve cancer detection accuracy. TeUS data were 272 acquired from 157 subjects during fusion prostate biopsy. This model achieves a ROC-273 AUC value of 0.96.

275 The various levels of accuracy are affected by several factors, including the model of AI, 276 modes of TRUS, amount of input data, Gleason grading, and PSA levels. Modes of TRUS 277 are significantly associated with accuracy, where the DCE-US/SWE/TeUS will improve 278 the visualisation and differentiation of prostate tissues compared to the B-mode. The 279 amount of input data is also an essential factor in making an accurate result in ANN 280 models. More complex data will create a more precise diagnosis.[44] Studies by Lee et 281 al.[27] and Wildeboer et al.[29] revealed that more data combinations would increase the 282 ROC-AUC value, increasing accuracy. Wildeboer et al. [29] showed a significant 283 relationship in Gleason score > 3+4, but no significant result in Gleason score 3+3 or 3+4. 284 This might be due to a bias in patient selection; tumors in 3+3 are considered 285 disproportionately large for clinicians, thus, not included in the study. Based on a study 286 by Lee et al. [27], the ROC-AUC of ANN models is consistently higher in PSA levels above 10. This might be associated with serum PSA levels which correlate with the extent of 287 288 cancer and histological grade [46] Thus, TRUS is not reliable to detect PCa as a single 289 tool. However, with utilization of machine learning and combinations of relevant input 290 data, TRUS has a potential role.

291

292 Future Development of Machine Learning-TRUS Model

The machine learning field is advancing rapidly and is supported by new hardware and software technology development. High-resolution and multiparametric imaging can be fused and integrated with other data sets to diagnose prostate cancer better.[47,48] The utilization of machine learning with TRUS data could have a potential role as a diagnostic modality, especially where MRI is not available. Based on the current guidelines, T2-

298 weighted imaging remains the most useful imaging method for local imaging on MRI.[49] 299 However, a meta-analysis by Rooij et al. [50] MRI has high specificity but poor sensitivity 300 for local PCa staging with sensitivity and specificity for extracapsular extension (ECE). 301 seminal vesicle invasion (SVI), and overall stage T3 detection of 0.57 (95% confidence 302 interval [CI] 0.49-0.64) and 0.91 (95% CI 0.88-0.93), 0.58 (95% CI 0.47-0.68) and 0.96 303 (95% CI 0.95-0.97), and 0.61 (95% CI 0.54-0.67) and 0.88 (95% CI 0.85-0.91), 304 respectively. Our findings showed that machine learning with TRUS other relevant data could increase the diagnostic performance. Thus, it will become more affordable and 305 306 easier to diagnose PCa by not performing MRI. Furthermore, the use of TRUS with 307 machine learning can be implemented as a fused combination with MRI to do a prostate 308 biopsy and intraoperative mapping to register preoperative MRI during robotic surgery. 309 This feature allows the surgeon to visualize the suspected lesions on the instrument 310 display during the procedure.

311

312 Limitation of the Study

313 We provide all available evidence about machine learning models of human ultrasound 314 images in prostate cancer diagnosis. However, none of the articles shows the same 315 output parameters to generate a quantitative analysis. Our approach included a 316 comprehensive search of multiple databases as well as other sources for relevant 317 publications. Since we restricted our literature search in English, some articles in other 318 languages may be missed out. The major weakness of this study is low to moderate 319 guality of included studies and the limited number of studies. Although there was only 320 limited evidence, we managed to analyse the predominant findings comprehensively.

321

322 Conclusions

Machine learning with neural network models is a potential technology in prostate cancer that could provide instant information for further workup with relatively high accuracy above 70% of sensitivity/specificity and above 0.5 of ROC-AUC value. Image-based machine learning models would be helpful for doctors to decide whether or not to perform a prostate biopsy. Future development of this technology will be further beneficial in making a diagnosis and treatment evaluation and patient prognosis.

329

330 Acknowledgement

331 Technical assistance and critical advice are provided by the staff of the Department of

332 Urology, Ciptomangunkusumo National Hospital.

333

334 Conflict of Interest

The authors report no conflict of interest. The authors alone are responsible for the content and writing of this article.

337 Funding

338 We have no funding providers on this paper.

339 **REFERENCES**

- 340 1. Sung H, Ferlay J, Siegel RL, Lavarsanne M, Soerjomataram I, Jemal A, et al.
- 341 Global cancer statistic 2020: GLOBOCAN estimates of incidence and mortality

- worldwide for 36 cancers in 185 countries. *Cancer Journal for Clinicians*.
 2021;71(3):209-249.
- Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific
 antigen test: a review of current evidence. *JAMA*. 2014;311:1143.
 https://pubmed.ncbi.nlm.nih.gov/24643604
- Naji L, Randhawa H, Sohani Z, Dennis B, Lautenbach D, Kavanagh O, et al.
 Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A
 Systematic Review and Meta-Analysis. *Ann Fam Med.* 2018;16:149.
 https://pubmed.ncbi.nlm.nih.gov/29531107
- Kretschmer A, Tilki D. Biomarkers in prostate cancer Current clinical utility and
 future perspectives. *Crit Rev Oncol Hematol*. 2017;120:180.
 https://pubmed.ncbi.nlm.nih.gov/29198331
- Bratan F, Niaf E, Melodelima C, Chesnais AL, Souchon R, Mege-Lechevallier F,
 et al. Influence of imaging and histological factors on prostate cancer detection
 and localisation on multiparametric MRI: a prospective study. *Eur Radiol*. 2013;23
- 357 2019. https://pubmed.ncbi.nlm.nih.gov/23494494
- Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic
 review of complications of prostate biopsy. *Eur Urol.* 2013;64:876–892. https://doi.
 org/10.1016/j.eururo.2013.05.049
- 3617.Ukimura O, Coleman JA, de la Taille A, Emberton M, Epstein JI, Freedland SJ, et
- al. Contemporary role of systematic prostate biopsies: indications, techniques,
- and implications for patient care. *Eur Urol*. 2013;63:214–230

- 364 8. Ganie FA, Wanie MS, Ganie SA, Lone H, Gani M, Mir MF, et al. Correlation of
 365 transrectal ultrasono- graphic findings with histopathology in prostatic cancer. *J* 366 *Educ Health Promot.* 2014;3:38.
- 367 9. Chen FK, Abreu ALC, Palmer SL. Utility of ultrasound in the diagnosis, treatment
 368 and follow-up of prostate cancer: State of the art. *J Nucl Med.* 2016;57:13S-18S.
- Kuligowska E, Barish MA, Fenlon HM, Blake M. Predictors of prostate carcinoma:
 accuracy of gray-scale and color dopples US and serum markers. *Radiology*.
 2001;220(3):757-64.
- 11. Leen E, Averkiou M, Arditi M, Burns P, Bokor D, Gauthier T, et al. Dynamic
 contrast enhanced ultrasound assessment of the vascular effects of novel
 therapeutics in early stage trials. *Eur Radiol.* 2012;22:1442–1450.
- 375 12. Sen J, Choudhary L, Marwah S, Godara R, Marwah N, Sen R. Role of colour
 376 doppler imaging in detecting prostate cancer. *Asian J Surg.* 2008;31(1):16-19.
- 377 13. Sang L, Wang X, Xu D, Cai Y. Accuracy of shear wave elastography for the
 378 diagnosis of prostate cancer: a meta-analysis. *Scientific Reports*. 2017;7.
- Lin CY, Yi T, Gao YZ, Zhou JH, Huang QH. Early detection and assessment of
 liver fibrosis by using ultrasound RF time series. *Journal of Medical and Biological Engineering*. 2017;37(5):717–729.
- Lin Q, Zhou J, Wang J, Li Q, Li A, Lin C, et al. Ultrasonic RF time series for early
 assessment of tumor response to chemotherapy: First in vivo studies on mice
 breast cancer model. *Ultrasound in Medicine and Biology*. 2017;43:p. S3.

- Liu G, Wu S, Huang L. Contrast-enchanced ultrasound evaluation of the prostate
 before transrectal ultrasound-guided biopsy can improve diagnostic sensitivity.
 Medicine. 2020;99(19):e19946.
- Li H, Xia J, Xie S, Guo Y, Xin M, Li F. Prostate cancer: a comparison of the
 diagnostic performance of transrectal ultrasound versus contrast enchanced
 transrectal ultrasound in different clinical characteristics. *Int J Clin Exp.* 2015;8(11):21428-21434.
- 392 18. Russell Stuart J, Norvig P. Artificial Intelligence: A Modern Approach; Prentice
 393 Hall: Upper Saddle River, NJ, USA, 2009; ISBN 0-13-207148-7
- Nichols JA, Chan HWH, Baker MAB. Machine learning: applications of artificial
 intelligence to imaging and diagnosis. *Biopsy Rev.* 2019;11(1):111-118.
- Nitta S, Tsutsumi M, Sakka S, Endo T, Hashimoto K, Hasegawa M, et al. Machine
 learning methods can more efficiently predict prostate cancer compared with
 prostate-specific antigen density and prostate-specific antigen velocity. *Prostat Intl.* 2019;7(3):114-118.
- 400 21. Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, Marberger M. Novel artificial neural
 401 network for early detection of prostate cancer. *J Clin Oncol*. 2002;20:921–929.
 402 doi:10.1200/JCO.2002.20.4.921
- 403 22. Aldoj N, Lukas S, Dewey M, Penzkofer T. Semi-Automatic Classification of Prostate
 404 Cancer on Multi-Parametric MR Imaging Using a Multi-Channel 3D Convolutional
 405 Neural Network. *Eur Radiol.* 2020, *30*, 1243–1253.

- Wang J, Wu CJ, Bao ML, Zhang J, Wang XN, Zhang YD. Machine learning-based
 analysis of MR radiomics can help to improve the diagnostic performance of PI-
- 408 RADS v2 in clinically relevant prostate cancer. *Eur Radiol*. 2017;27:4082–4090.
- 409 24. Ronco AL, Fernandez R. Improving ultrasonographic diagnosis of prostate cancer
 410 with neural networks. *Ultrasound in Med and Biol*. 1999;25(5):729-733.
- Loch T, Leuschner I, Genberg C, Weichert-Jacobsen K, Kuppers F, Yfantis E, et
 al. Artificial neural network analysis of prostatic transrectal ultrasound. *The prostate*. 1999;39(1):198-204.
- Lee JH, Hwang SI, Han SM, Park SH, Kim SH, Cho JY, Seong CG. Imaged-based
 clinical decision support for transrectal ultrasound in the diagnosis of prostate
 cancer: comparison of multiple logistic regression, artificial neural network, and
 support vector machine. *Eur Radiol*. 2010;20(1):1476-1484.
- 418 27. Lee HJ, Kim KG, Lee SE, Byun SS, Hwang SI. Jung SI, et al. Role of transrectal
 419 ultrasonography in the prediction of prostate cancer: artificial neural network
 420 analysis. *J Ultrasound Med.* 2006;25(7):815-21.
- 421 28. Azizi S, Bayat S, Yan P, Tahmasebi A, Kwak JT, Xu S, et al. Deep recurrent neural
 422 networks for prostate cancer detection: Analysis of temporal enhanced
 423 ultrasound. *IEEE Transactions on Medical Imaging.* 2018;37(12):2695-2703.
- Wildeboer RR, Mannaerts CK, Sloun RJG, Budaus L, Tilki D, Wijkstra H, et al.
 Automated multiparametric localisation of prostate cancer based on B-mode,
 shear-wave elastography, and contrast-enhanced iltrasoundradiomics. *Eur Radiol.* 2020;30(1):806-815.

Ghose S, Oliver A, Marti R, Llado X, Freixenet J, et al. A survey of prostate
segmentation methodologies in ultrasound, magenetic resonance and computed
tomography images. *Comput Methods Programs Biomed.* 2012;108(1):262-87.

- 31. Drost FH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al.
 Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for
 detecting prostate cancer. *Cochrane Database Syst Rev.* 2019;4: CD012663.
- 32. Sun Y, Reynolds HM, Parameswaran B, Wraith D, Finnegan M, Williams S, et al.
 Multiparametric MRI and radiomics in prostate cancer: a review. *Australias Phys Eng Sci Med.* 2019;42:3–25.
- 33. van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, et
 al. Head-to-head comparison of transrectal ultrasound-guided prostate biopsy
 versus multiparametric prostate resonance imaging with subsequent magnetic
 resonance-guided biopsy in biopsy-naïve men with elevated prostate-specific
 antigen: a large prospective multicenter clinical study. *Eur Urol.* 2019;75:570–578.
- 442 34. Winoker JS, Pinto PA, Rastinehad AR. MRI to guide biopsies or avoid biopsies?
 443 *Curr Opin Urol.* 2018;28:522–528.
- 35. Smeenge M, Barentsz J, Cosgrove D, de la Rosette J, de Reijke T, Eggener S, et
 al. Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer:
 report from a Consensus Panel. *BJU Int.* 2012;110: 942-8.
- 447 36. Taneja SS. Imaging in the diagnosis and management of prostate cancer. *Rev*448 *Urol.* 2004;6(3):101-113.
- 37. Correas JM, Halpern EJ, Barr RG, Ghai S, Walz J, Bodard S, et al. Advanced
 ultrasound in the diagnosis of prostate cancer. *World J Urol.* 2020.

- 38. Claudon M, Cosgrove D, Albrecht T. Guidelines and good clinical practice
 recommendations for contract enchanced ultrasound. *Ultraschall in der Medizin- European Journal of Ultrasound*. 2008;29(1):28-44.
- 454 39. Kuenen MPJ, Mischi M, Wijkstra H. Contrast-ultrasound diffusion imaging for
 455 localisation of prostate cancer. *IEEE Transactions on Medical Imaging*.
 456 2011;30(8):1493.
- 40. Lughezzani G, Saita A, Lazzeri M, Paciotti M, Maffei D, Lista G, et al. Comparison
 of the diagnostic accuracy of micro-ultrasound and magnetic resonance
 imaging/ultrasound fusion targeted biopsies for the diagnosis of clinically
 significant prostate cancer. *Eur Urol Oncol.* 2019;2:329–332.
- 461 41. Loch T. Computerized transrectal ultrasound (C-TRUS) of the prostate: detection
 462 of cancer in patients with multiple negative systematic random biopsies. *World J*463 *Urol.* 2007;25:375–380.
- 464 42. Zhang M, Tang J, Luo Y, Wang Y, Wu M, Memmott B, et al. Diagnostif
 465 performance of multiparametric transrectal ultrasound in localized prostate
 466 cancer: A comparative study with magnetic resonance imaging. *J Ultrasound in*467 *Med.* 2018;38(7):1823-1830.
- 468 43. Brattain LJ, Telfer BA, Dhyani M, Grajo JR, Samir AE. Machine learning for
 469 medical ultrasound: status, method, and future opportunities. Abdom Radiol.
 470 2018;43(4):786-799.
- 47. 44. Noorbakhsh-Sabet N, Zand R, Zhang Y, Abedi V. Artificial Intelligence Transforms
 47. the Future Healthcare. *Am J Med*. 2019;132(7):795-801.

- 473 45. Alaloul WS. Qureshi AH. Data processing using artificial neural networks. *Intech*474 *Open*. 2020.
- 46. Carter HB. Differentiation of lethal and non-lethal prostate cancer: PSA and PSA
 isoforms and kinetics. *Asian J Androl.* 2012;14(3):355-360.
- 477 47. Tătaru OS, Vartolomei MD, Rassweiler JJ, Virgil O, Lucarelli G, Porpiglia F, et al.
 478 Artificial intelligence and machine learning in prostate cancer patient
 479 management—current trends and future perspectives. *Diagnostics*.
 480 2021;11(2):1–20.
- 481 48. Goldenberg SL, Nir G, Salcudean SE. A new era: artificial intelligence and 482 machine learning in prostate cancer. *Nat Rev Urol*. 2019;16(7):391–403.
- 483 49. Mottet N, Conford P, van den Bergh RCN, Briers E, Santis MD, Gillessen S, et al.
 484 EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer.
 485 EAU;2021.
- 486 50. Rooij M, Hamoen EHJ, Futterer JJ, Barentsz JO, Roevers MM. Accuracy of
 487 magnetic resonance imaging for local staging of prostate cancer: a diagnostic
 488 meta-analysis. AJR Am J Roentgenol. 2016;70(2):233-45.

Figure 1. Prisma Flow Diagram



Figure 1



Figure 2. Risk of Bias Assessment using QUADAS-2 Tool

Figure 2



Figure 3. Schematic Machine Learning Model in Prostate Cancer Diagnosis

Figure 3